비호지킨 림프종 CAR-T 세포치료 : 시장 인사이트, 역학 및 시장 예측(2036년)

Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Insights and Trends

• According to DelveInsight's analysis, the CAR T-cell in the NHL market size was found to be ~USD 3,200 million in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• CAR-T cells provide a long-term benefit with a one-time treatment, avoiding the toxicity of salvage chemotherapy and autologous transplant for patients with high-risk illnesses. The approvals have altered the standard of care for high-risk patients who are either primary refractory or have early recurrence following front-line therapy.
• Therapeutic management of CAR T-cell Therapy in NHL is primarily focused on achieving deep and durable remission, particularly in relapsed or refractory settings, by targeting specific tumor antigens such as CD19, with treatment strategies tailored based on disease subtype, stage, and prior lines of therapy.
• The current CAR T-cell therapy landscape in NHL is evolving rapidly, with increasing adoption across multiple indications including Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), Marginal Zone Lymphoma (MZL), and Chronic Lymphocytic Leukemia (CLL)/small lymphocytic lymphoma (SLL), driven by high unmet need in relapsed/refractory populations, expansion into earlier lines of therapy (2L+ and select 1L settings), and improved patient stratification based on transplant eligibility and disease stage.
• The CAR T-cell therapy market in NHL comprises several approved and emerging therapies across different lines of treatment, including TECARTUS, BREYANZI, KYMRIAH, and YESCARTA, alongside investigational therapies such as CTX110, Zamtocabtagene autoleucel, Cemacabtagene Ansegedleucel, Rapcabtagene autoleucel, and MB-106, reflecting strong innovation and competitive dynamics.
• Despite notable progress, the CAR T-cell therapy pipeline in NHL remains moderately sized, with ongoing efforts focused on expanding into indications such as MCL, DLBCL, FL, PMBCL, MZL, and CLL/SLL, while also enhancing safety, accessibility, and durability through next-generation and allogeneic approaches.

DelveInsight's 'Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's lymphoma (NHL), historical and forecasted epidemiology, as well as Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's lymphoma (NHL) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's lymphoma (NHL) patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's lymphoma (NHL) and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Market

Rising NHL Incidence Cases

The rising incidence of NHL, especially aggressive subtypes like DLBCL, is fueling greater adoption and market growth for CAR T-cell therapy. In the US, 2025 saw approximately 68,000 new cases of NHL indications suitable for CAR-T, a figure projected to expand at a significant CAGR through 2036.

Rising Opportunities in CAR T-Cell Therapies in NHL

Emerging clinical evidence demonstrating the strong efficacy and durable responses of CAR T-cell therapy across relapsed and refractory NHL highlights a growing opportunity for drug developers to focus on next-generation and allogeneic CAR T-cell approaches, aiming to improve accessibility, safety, and long-term outcomes.

Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Understanding and Treatment Algorithm

Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Overview and Diagnosis

CAR T-cell therapy is a personalized immunotherapy in which a patient's T cells are modified to target cancer cells, most often CD19-positive B-cell NHL. After reinfusion, these engineered cells identify and destroy malignant cells. It is especially used for relapsed or refractory aggressive lymphomas such as DLBCL. While it has improved outcomes for patients with few other options, careful patient selection is important because the treatment can cause significant toxicities.

Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Diagnosis

In general, the diagnosis of NHL relies on biopsy as the gold standard to confirm the disease and determine its subtype. This is supported by physical examination, imaging tests such as CT, MRI, and PET-CT to assess disease spread, and bone marrow evaluation. Additionally, biomarker and molecular testing (including NGS, flow cytometry, and immunohistochemistry) help identify specific tumor characteristics and guide advanced treatments like CAR T-cell Therapy.

Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Treatment

The primary goals of treatment with CAR T-cell Therapy in NHL are to achieve rapid and durable remission, eliminate malignant B cells, prevent disease progression or relapse, and improve overall survival and quality of life, particularly in relapsed or refractory settings. Management is highly specialized and involves lymphodepleting chemotherapy followed by CAR T-cell infusion, with close monitoring for treatment-related toxicities such as cytokine release syndrome and neurotoxicity. CAR T-cell therapies-including TECARTUS, BREYANZI, KYMRIAH, and YESCARTA target CD19-positive B cells and are primarily used in later lines of therapy, with expanding use into earlier treatment settings.

Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Unmet Needs

The section "unmet needs of Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's lymphoma (NHL)" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. CAR-T cell-associated toxicities

2. Optimizing CAR-T cells' therapeutic window

3. Ready to use off-the-shelf CAR-T cell therapy

4. Slow prior authorization process and others.....

Comprehensive unmet needs insights in Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's lymphoma (NHL) and their strategic implications are provided in the full report.

Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Epidemiology

Key Findings from Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Epidemiological Analysis and Forecast

• According to DelveInsight estimates, the total incident cases of selected CAR-T indications in NHL across the 7MM were approximately 159,000 in 2025 and are expected to rise throughout the forecast period from 2026 to 2036.
• Across the 7MM, CAR T-cell therapy demonstrates promising potential in multiple NHL indications, including MCL, DLBCL (with the highest number of incident cases around 78,000), FL, PMBCL, MZL, and CLL/SLL.
• The United States had the highest incidence of selected CAR-T indications in NHL, with approximately 68,000 cases in 2025.

Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Drug Chapters & Competitive Analysis

The CAR T- cell in NHL drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the CAR T- cell in the NHL treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the CAR T- cell in the NHL therapeutics market.

Approved Therapies for Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL)

YESCARTA (axicabtagene ciloleucel): Gilead Sciences (Kite Pharma)

YESCARTA, developed by Gilead Sciences (Kite Pharma), is an autologous CD19-directed CAR T-cell therapy administered via intravenous infusion (cell suspension). It was approved by the US FDA in October 2017 for adults with relapsed or refractory large B-cell lymphomas, including diffuse large B-cell lymphoma. It works by genetically modifying a patient's T cells to express a CAR targeting CD19, leading to T-cell activation, proliferation, and targeted killing of malignant B cells.

KYMRIAH (tisagenlecleucel): Novartis

KYMRIAH, developed by Novartis, is a CD19-directed autologous CAR T-cell therapy administered via intravenous infusion. It was first approved by the US FDA in August 2017 and later expanded for adult patients with relapsed or refractory large B-cell lymphoma. It works by genetically modifying a patient's T cells to express a chimeric antigen receptor (CAR) that recognizes CD19 on malignant B cells, leading to T-cell activation, proliferation, and targeted elimination of cancer cells.

Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Pipeline Analysis

Cemacabtagene ansegedleucel: Allogene Therapeutics

Cemacabtagene ansegedleucel (ALLO-501A), a next-generation anti-CD19 AlloCAR-T, is engineered without the rituximab recognition domains included in ALLO-501, which could allow for use in a broader patient population, including NHL patients with recent rituximab exposure; cemacabtagene ansegedleucel uses the Cellectis TALEN technology.

Rapcabtagene autoleucel: Novartis

Rapcabtagene autoleucel, an investigational, autologous CD19-directed CAR-T-cell therapy developed using the T-charge platform, showed promising results in the DLBCL arm of a first-in-human, multicenter, Phase I dose-escalation study.

Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Key Players, Market Leaders, and Emerging Companies

• Gilead Sciences (Kite Pharma)
• Novartis
• BMS
• Bristol Myers Squibb
• Miltenyi Biomedicine
• Wugen
• Autolus Therapeutics
• 2seventy bio
• Imugene
• MustangBio
• CRISPR Therapeutics
• Tessa Therapeutics
• PeproMene Bio
• Johnson & Johnson Pharmaceutical Research and Development
• Adicet Bio
• Juno Therapeutics
• Takeda, and others

Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Drug Updates

• In April 2026, the US FDA granted full approval to TECARTUS for adult patients with relapsed or refractory MCL, supported by efficacy, safety, and pharmacokinetic data from the ZUMA-2 study, including patients who are BTKi-naive after one or more prior lines of therapy.
• In February 2026, Gilead Sciences (Kite) announced that the US FDA approved an update to YESCARTA labeling, removing the prior limitation of use in patients with relapsed or refractory primary CNS lymphoma (PCNSL), reinforcing its safety profile and making it the only CAR T-cell therapy with this restriction removed for large B-cell lymphoma.
• In December 2025, the US FDA approved BREYANZI as the first CART-cell Therapy in the US for adults with MZL who have relapsed or failed after two or more prior lines of therapy, where it works by engineering a patient's T cells to target and destroy cancer cells.

Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Market Outlook

The CAR T-cell Therapy market in NHL is undergoing a significant transformation following years of reliance on chemo-immunotherapy and stem cell transplantation. The approvals and expanding use of CAR T-cell therapies such as TECARTUS, BREYANZI, KYMRIAH, and YESCARTA mark a shift toward highly targeted, cell-based immunotherapy, enabling durable responses in relapsed or refractory patients. These advances validate antigen-specific approaches, reinforce regulatory and clinical confidence in cellular therapies, and are reshaping the competitive landscape by expanding treatment options and accelerating innovation across the NHL pipeline.

With continued advancements in next-generation and allogeneic CAR T-cell therapies, the NHL treatment landscape is evolving similarly to other oncology areas, where early approvals drive broader therapeutic expansion into earlier lines of therapy and additional indications. The United States remains the largest market, supported by higher diagnosis rates, strong adoption of advanced therapies, and faster uptake of innovation compared to the EU4, the United Kingdom, and Japan.

Overall, the introduction of first-in-class CAR T-cell therapies, improvements in patient identification, and increasing awareness of advanced treatment options are expected to drive steady growth in the 7MM NHL market over the forecast period, with significant commercial potential for both approved products and emerging pipeline candidates.

• According to the estimates, the United States accounted for the largest CAR T-cell therapy market in NHL, valued at approximately USD 1,900 million in 2025, and is expected to grow at a significant CAGR.
• The CAR T-cell therapy market in NHL is rapidly evolving as treatment approaches shift from conventional chemo-immunotherapy to highly targeted, cell-based therapies, with increasing adoption driven by strong efficacy in relapsed/refractory settings, expansion into earlier lines of therapy (2L, 3L+), and advancements in next-generation and allogeneic CAR T platforms.
• Regional market dynamics indicate that the United States leads in revenue and adoption due to early approvals and robust healthcare infrastructure, while Japan and EU markets are witnessing steady growth, supported by rising disease incidence, improving access to advanced therapies, and increasing uptake of novel CAR T-cell treatments.
• In the EU4 and the UK, Germany held the largest market share, followed by Italy, while Spain had the smallest market size.
• In 2036, among all the therapies for CAR T- cell in NHL, the highest revenue is estimated to be generated by DLBCL in the United States.
• The entry of emerging and late-stage CAR T-cell therapies is expected to intensify competition in the CAR T-cell therapy landscape for NHL during the forecast period, with key indications such as MCL and FL representing leading areas of focus and growth.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's lymphoma (NHL) (2022-2036 Forecast)

The CAR T-cell therapy market in NHL comprises autologous CAR T-cell therapies, next-generation/advanced CAR T constructs, emerging allogeneic ("off-the-shelf") therapies, and conventional chemo-immunotherapy, each targeting distinct biological mechanisms underlying B-cell malignancies and immune evasion. CAR T-cell therapy treats cancer by genetically engineering T cells to express chimeric antigen receptors (CARs) that specifically recognize tumor-associated antigens (e.g., CD19) on malignant B cells, enabling direct targeting, activation, and destruction of cancer cells along with sustained immune surveillance.

• Autologous CAR T-cell therapies: Products such as YESCARTA and KYMRIAH are CD19-directed therapies that genetically modify a patient's own T cells to recognize and eliminate malignant B cells. These therapies provide durable responses in relapsed or refractory NHL, establishing personalized, mechanism-driven immunotherapy as a transformative treatment approach.
• Next-generation/advanced CAR T-cell therapies: Therapies such as BREYANZI and TECARTUS incorporate optimized manufacturing processes, controlled cell composition, and improved safety profiles. These advancements enhance efficacy and tolerability, enabling broader application across NHL subtypes, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).
• Allogeneic CAR T-cell therapies (emerging): Off-the-shelf CAR T products derived from healthy donors are being developed to overcome manufacturing delays and scalability limitations of autologous approaches. These therapies aim to provide rapid treatment access and consistent product quality, representing a key future direction in CAR T innovation.

Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the CAR T- cell in the NHL market's uptake by drugs, patient uptake by therapy, and sales of each drug.

The uptake of therapies in CAR T-cell Therapy for NHL is expected to vary across approved autologous products, next-generation CAR T-cell therapies, and emerging allogeneic platforms. Established therapies such as BREYANZI, KYMRIAH, and YESCARTA demonstrate strong and growing uptake, supported by robust efficacy in relapsed or refractory settings, expanding label indications, and increasing physician confidence in managing treatment-related toxicities. Their adoption is further driven by the limitations of conventional chemo-immunotherapy in achieving durable remission and the high unmet need in aggressive B-cell lymphomas.

In comparison, next-generation and investigational therapies such as CTX110 and Cemacabtagene Ansegedleucel are expected to show gradual but steady uptake as clinical evidence matures, manufacturing challenges are addressed, and these off-the-shelf approaches are increasingly integrated into treatment paradigms across diverse NHL subtypes.

Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Therapies Price Scenario & Trends

Pricing and analogue assessment of CAR T- Cell in NHL therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, the closest and most appropriate analogue selection for emerging therapies, and the understanding of how pricing influences market access, adherence, and long-term uptake.

• Pricing of Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Approved Drugs

For BREYANZI in the treatment of follicular lymphoma, the recommended dosage ranges from 90 to 110 X 106 CAR-positive viable T cells, with an approximate price of USD 410,300 per treatment.

Further details are provided in the final report....

Industry Experts and Physician Views for Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL)

To keep up with CAR T- cell in NHL market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the CAR T- cell in NHL emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in CAR T- cell in NHL, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 6+ KOLs in the 7MM. Centers such as the National Cancer Center Hospital, University of Pennsylvania, NCI's Center for Cancer Research, and Sarah Cannon Research Institute, etc. were contacted. Their opinion helps understand and validate current and emerging CAR T-cell therapies in NHL therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in CAR T- cell in NHL.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's lymphoma (NHL), strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are mainly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of CAR T-cells in NHL, explaining its causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the CAR T- cell in the NHL market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM CAR T- cell in the NHL market.

Report Insights

• Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Patient Population Forecast
• Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Therapeutics Market Size
• Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Pipeline Analysis Lymphoma
• Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Market Size and Trends
• Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-enabled Market Research Report
• 11-year forecast
• Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (by geography)
• Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Treatment Addressable Market (TAM)
• Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Competitive Landscape
• Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Major Companies Insights
• Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Price Trends and Analogue Assessment
• Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Therapies Drug Adoption/Uptake
• Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Therapies Peak Patient Share analysis

Report Assessment

• Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Current Treatment Practices
• Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Unmet Needs
• Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Clinical Development Analysis
• Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Emerging Drugs Product Profiles
• Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Market Attractiveness
• Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL) Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

Market Insights

• What was the Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's lymphoma (NHL) market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's lymphoma (NHL)?
• What are the disease risks, burdens, and unmet needs of Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's lymphoma (NHL)? What will be the growth opportunities across the 7MM concerning the patient population with Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's lymphoma (NHL)?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's lymphoma (NHL)? What are the current guidelines for treating Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's lymphoma (NHL) in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's lymphoma (NHL) market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights into the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

• 4.1. Upcoming Key Catalysts
• 4.2. Key Transactions And Collaborations
• 4.3. News Flow

5. Epidemiology and Market Forecast Methodology

6. CAR T- cell in NHL Market Overview at a Glance

• 6.1. Emerging Landscape Analysis (By Phase, Molecule Type, and RoA)
• 6.2. Market Share (%) Distribution of CAR T-cells in NHL by Therapies in the 7MM, in 2025
• 6.3. Market Share (%) Distribution of CAR T-cells in NHL by Therapies in the 7MM, in 2036

7. Disease Background and Overview of Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL)

• 7.1. Introduction
• 7.2. Understanding Lymphoma
  • 7.2.1. Types of Lymphoma
  • 7.2.2. Types of NHL
• 7.3. Signs and Symptoms
• 7.4. Staging
• 7.5. Diagnosis of NHL

8. Treatment of Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL)

9. Treatment Guidelines

• 9.1. NCCN Guidelines for Diffuse Large B-Cell Lymphoma
• 9.2. NCCN Guidelines for Follicular Lymphoma

10. Epidemiology and Patient Population of Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL)

• 10.1. Key Findings
• 10.2. Assumptions and Rationale
• 10.3. Epidemiology Scenario in the 7MM
• 10.4. The United States
  • 10.4.1. Total NHL incident cases in selected subtypes in the United States
  • 10.4.2. Total eligible cases of NHL for CAR-T in the United States
• 10.5. EU4 and the UK
  • 10.5.1. Total NHL incident cases in selected subtypes in the EU4 and the UK
  • 10.5.2. Total eligible cases of NHL for CAR-T in the EU4 and the UK
• 10.6. Japan
  • 10.6.1. Total NHL incident cases in selected subtypes in Japan
  • 10.6.2. Total eligible cases of NHL for CAR-T in Japan

11. Patient Journey of Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL)

12. Marketed Therapies

• 12.1. Marketed Competitive Landscape of Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL)
• 12.2. YESCARTA (axicabtagene ciloleucel): Gilead Sciences (Kite Pharma)
  • 12.2.1. Drug Description
  • 12.2.2. Regulatory Milestones
  • 12.2.3. Other Developmental Activities
  • 12.2.4. Summary of Pivotal Trials
  • 12.2.5. Clinical Development
    • 12.2.5.1. Clinical Trial Information
  • 12.2.6. Analyst's Views
• 12.3. KYMRIAH (tisagenlecleucel): Novartis
  • 12.3.1. Drug Description
  • 12.3.2. Regulatory Milestones
  • 12.3.3. Other Developmental Activities
  • 12.3.4. Summary of Pivotal Trials
  • 12.3.5. Clinical Development
    • 12.3.5.1. Clinical Trial Information
  • 12.3.6. Analyst's Views
• 12.4. BREYANZI (lisocabtagene maraleucel): Bristol Myers Squibb
  • 12.4.1. Drug Description
  • 12.4.2. Regulatory Milestones
  • 12.4.3. Other Developmental Activities
  • 12.4.4. Summary of Pivotal Trials
  • 12.4.5. Clinical Development
    • 12.4.5.1. Clinical Trial Information
  • 12.4.6. Analyst's Views
• 12.5. TECARTUS (brexucabtagene autoleucel): Gilead Sciences (Kite Pharma)
  • 12.5.1. Drug Description
  • 12.5.2. Regulatory Milestones
  • 12.5.3. Other Developmental Activities
  • 12.5.4. Summary of Pivotal Trials
  • 12.5.5. Analyst's Views

13. Emerging Drugs

• 13.1. Emerging Competitive Landscape of Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL)
• 13.2. Rapcabtagene autoleucel: Novartis
  • 13.2.1. Drug Description
  • 13.2.2. Other Developmental Activities
  • 13.2.3. Clinical Development
    • 13.2.3.1. Clinical Trials Information
  • 13.2.4. Analyst's Views
• 13.3. Zamtocabtagene autoleucel: Miltenyi Biomedicine
  • 13.3.1. Drug Description
  • 13.3.2. Other Developmental Activity
  • 13.3.3. Clinical Development
    • 13.3.3.1. Clinical Trials Information
  • 13.3.4. Analyst's Views
• 13.4. MB-106: Mustang Bio
  • 13.4.1. Drug Description
  • 13.4.2. Clinical Development
    • 13.4.2.1. Clinical Trial Information
  • 13.4.3. Safety and Efficacy
  • 13.4.4. Analyst's Views
• 13.5. CTX110: CRISPR Therapeutics
  • 13.5.1. Drug Description
  • 13.5.2. Clinical Development
    • 13.5.2.1. Clinical Trial Information
  • 13.5.3. Safety and Efficacy
  • 13.5.4. Analyst's Views
• 13.6. bbT369: 2seventy bio
  • 13.6.1. Drug Description
  • 13.6.2. Clinical Development
    • 13.6.2.1. Clinical Trial Information
  • 13.6.3. Safety and Efficacy
  • 13.6.4. Analyst's Views
• 13.7. Azercabtagene zapreleucel: Imugene
  • 13.7.1. Drug Description
  • 13.7.2. Clinical Development
    • 13.7.2.1. Clinical Trial Information
  • 13.7.3. Safety and Efficacy
  • 13.7.4. Analyst's Views

14. Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL): 7MM Analysis

• 14.1. Key Findings
• 14.2. Market Outlook of Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL)
• 14.3. Key Market Forecast Assumptions
  • 14.3.1. Cost Assumptions
• 14.4. Conjoint Analysis of Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL)
• 14.4. Total Market Size of CAR T- Cell in NHL in the 7MM
• 14.4. Total Market Size of CAR T- Cell in NHL by Therapies in the 7MM
• 14.4. The United States
  • 14.7.1. Total Market Size of CAR T- Cell in NHL in the United States
  • 14.7.2. Total Market Size of CAR T- Cell in NHL by Therapies in the United States
• 14.8. EU4 and the UK
  • 14.8.1. Total Market Size of CAR T- Cell in NHL in EU4 and the UK
  • 14.8.2. Total Market Size of CAR T- Cell in NHL by Therapies in EU4 and the UK
• 14.9. Japan
  • 14.9.1. Total Market Size of CAR T- Cell in NHL in Japan
  • 14.9.2. Total Market Size of CAR T- Cell in NHL by Therapies in Japan

15. Unmet Needs of Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL)

16. SWOT Analysis of Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL)

17. KOL Views of Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL)

18. Market Access and Reimbursement of Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin's Lymphoma (NHL)

• 18.1. The United States
• 18.2. EU4 and the UK
  • 18.2.1. Germany
  • 18.2.2. France
  • 18.2.3. Italy
  • 18.2.4. Spain
  • 18.2.5. United Kingdom
• 18.3. Japan
• 18.3. Summary and comparison of Market Access and Pricing Policy Developments in 2025
• 18.3. Market Access and Reimbursement of CAR T- CELL IN NHL Therapies

19. Appendix

• 19.1. Bibliography
• 19.2. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight